Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Antipsychotic

or None

Use the filters below to narrow your results.

Codeine (2)

None (9) · (multiple, generic dominant) (1) · Clozaril (1) · Compazine (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · ketalar (1) · Latuda (1) · Laudanum, Dropizol (1) · Lithobid (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Nubain (1) · Nucynta (1) · Nuedexta (1) · Opana (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stadol (1) · Stelazine (1) · Suboxone (1) · Talwin (1) · Thorazine (1) · Trilafon (1) · Ultracet, Tramacet (1) · Vicodin (1)

None (1) · 5HT1a (1) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multi-receptor antagonist; low D2 affinity (1) · NMDA-receptor antagonism (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phenothiazine D2 antagonist (5) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Source of DMT-class tryptamines (1) · Source of [[DMT]], bufotenine, and 5-MeO-DMT (1) · Source of [[DMT|N,N-dimethyltryptamine]] (1) · TBD (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00001580-QINU`"' First FDA-approved treatment for PBA. The 10 mg quinidine daily dose is far below antiarrhythmic levels but sufficient to nearly fully inhibit CYP2D6, the basis of the combination's pharmacokinetic rationale'"`UNIQ--ref-00001581-QINU`"'. (1) · µ-opioid agonism (1)

None (39) · Antimanic, Antidepressive, Antisuicide (1) · Mild to moderate pain; cough suppression (low-dose). (1) · Pain, cough, disquiet (1) · '"`UNIQ--vote-0000152F-QINU`"' (1) · '"`UNIQ--vote-00001582-QINU`"' (1)

None (41) · 1 capsule (20/10 mg dextromethorphan/quinidine) PO once daily × 7 days, then 1 capsule BID (1) · 2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (41) · 20 mg dextromethorphan HBr / 10 mg quinidine sulfate capsules (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tramadol/acetaminophen 37.5/325 mg tablets (1)

None (41) · 1 capsule BID (40 mg DXM / 20 mg quinidine per day) (1) · 360 mg/day (1) · 8 tablets/d (300 mg tramadol / 2600 mg acetaminophen); 5-day duration limit per label (1)

None (41) · Oral (2) · PO (only formulation marketed in the US). (1)

None (41) · 30-60 minutes (1) · 30–60 min (PO) (1) · PBA episode reduction within 1-2 weeks (1)

None (41) · 12 hours (1) · 4-6 hours (1) · 4–6 hours (1)

None (41) · 2.5–3 hours (1) · Dextromethorphan substantially prolonged by quinidine's CYP2D6 inhibition (typical extensive metabolizers see ~10× higher AUC); quinidine ~6-8 hours'"`UNIQ--ref-00001583-QINU`"' (1) · Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1)

None (41) · Increased substantially via CYP2D6 inhibition'"`UNIQ--ref-00001584-QINU`"' (1) · Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (41) · Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data; quinidine has been used in pregnancy as antiarrhythmic.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (41) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US. Caution with QT-prolonging medicines (quinidine itself is class IA antiarrhythmic, and the dose here, though sub-antiarrhythmic, still contributes to QT)'"`UNIQ--ref-00001585-QINU`"' (1) · [[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)

A

B

C

D

E

F

H

I

K

L

M

N

O

P

T

U

Z